Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia.
Acute myeloid leukaemia (AML) is a difficult to treat disease, especially for those patients who have no eligible haematopoietic stem cell (HSC) donor. One of the most promising treatment options for these patients is immunotherapy. To investigate the expression of known tumour antigens in AML, we analysed microarray data from 124 presentation AML patient samples and investigated the present/absent calls of 82 tumour-specific or -associated antigens. We found 11 antigens which were expressed in AML patient samples but not normal donors. Nine of these were cancer-testis (CT) antigens, previously shown to be expressed in tumour cells and immunologically protected sites and at very low levels, if at all, in normal tissues. Expression was confirmed using real-time PCR. We have identified a number of CT antigens with expression in presentation AML samples but not normal donor samples, which may provide effective targets for future immunotherapy treatments early in disease.
Guinn
Barbara-Ann
BA
Department of Haematological Medicine, Guy's, King's and St. Thomas' School of Medicine, King's College London, London SE5 9NU, UK. barbara.guinn@kcl.ac.uk
Gilkes
Amanda F
AF
Woodward
Eleanor
E
Westwood
Nigel B
NB
Mufti
Ghulam J
GJ
Linch
David
D
Burnett
Alan K
AK
Mills
Ken I
KI
D000208:Acute Disease; D000951:Antigens, Neoplasm / Q000276:immunology*; D001483:Base Sequence; D017931:DNA Primers; D006801:Humans; D007951:Leukemia, Myeloid / Q000276:immunology*; D020411:Oligonucleotide Array Sequence Analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction
D000951:Antigens, Neoplasm; D017931:DNA Primers